fowlpox-sargramostim
Recombinant proteinexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2001 (NCT00028496)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1
- Breast Neoplasms · Phase 1
- Breast Neoplasms, Male · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 1
- Intestinal Neoplasms · Phase 1
- Liver Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Salivary Gland Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1
- Testicular Neoplasms · Phase 1
- Thyroid Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- OrthopoxvirusImmunity, active
Orthopoxvirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fowlpox-sargramostim
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00091039 | N/A | Aug 1, 2004 | National Cancer Institute (NCI) |
| NCT00072137 | Phase 1 | Oct 1, 2003 | National Cancer Institute (NCI), Rutgers University |
| NCT00028496 | Phase 1 | Nov 1, 2001 | National Cancer Institute (NCI), Temple University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 3 | 2 | 2001 |
| Rutgers University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2001 |
3 organizations
Page 1 / 1